Viatris Inc Ordinary Shares VTRS 深 滬
已收盤 08-15 16:00:00 美东时间
10.61
-0.080
-0.75%
華盛通- 最 高10.81
- 今 開10.75
- 成交量 923.10万股
- 最 低 10.55
- 昨 收 10.69
- 總市值 124.56亿
- 52周最高 13.31
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 6.73
- 委 比 30.27%
- 總股本 11.74亿
- 歷史最高 16.85
- 量 比 0.63
- 振 幅 2.43%
- 歷史最低 6.73
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NusaTrip prices $15M IPO, set to begin trading on Nasdaq as "NUTR"
NusaTrip (NASDAQ:NUTR) priced its initial public offering at $4/share, offering 3.75M shares for $15M in gross proceeds. The company granted a 45-day option for underwriters to purchase up to 562,500 ...
08-15 22:07
David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades
David Einhorn's Greenlight Capital took new positions in Fluor (NYSE:FLR), with 760.6K shares, and Victoria's Secret (NYSE:VSCO), with 168.3K shares, during the second quarter of 2025, according to th...
08-15 00:09
美股盘后 | Insmed涨5.39%，Viatris Inc Ordinary Shares涨2.88%
Insmed涨5.39%；Viatris Inc Ordinary Shares涨2.88%；Sailpoint科技涨2.26%
08-14 06:11
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit
Perrigo faces a legal battle over whether major investor Sculptor can exit a securities class action years after missing the opt-out deadline amid $1 billion restatements.
08-14 02:28
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.
08-13 01:38
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer
Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer marketed by Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) ...
08-11 22:08
Twilio beats Q2 estimates, initiates Q3 outlook
Twilio press release (NYSE:TWLO): Q2 Non-GAAP EPS of $1.19 beats by $0.14. Revenue of $1.23B (+13.9% Y/Y) beats by $40M. Twilio is initiating guidance for the third quarter ending September 30, 2025. ...
08-08 04:25
SA Asks: How could higher India tariffs impact drug stocks?
India is a major supplier of prescription drugs, over-the-counter medications, and pharmaceutical ingredients to the United States. Recently, President Trump announced he intends to impose a 25% tari...
08-08 01:00
Viatris shares are trading higher after the company reported better-than-expected Q2 financial results.
Viatris shares are trading higher after the company reported better-than-expect...
08-07 22:27
Viatris Affirms FY2025 Adj EPS Guidance of $2.16-$2.30 vs $2.21 Est; Affirms FY2025 Sales Guidance of $13.500B-$14.000B vs $13.801B Est
Viatris (NASDAQ:VTRS) affirms FY2025 Adj EPS guidance from $2.16-$2.30 to $2.16-$2.30 vs $2.21 analyst estimate. Affirms FY2025 sales outlook from $13.500 billion-$14.000 billion to $13.500 billion-$14.000 billion vs
08-07 19:06
